SLC5A2 and type 2 diabetes mellitus: In the general population with type 2 diabetes it is recommended to introduce new classes of drugs, the efficacy of which has emerged in recent years (glucagon-like peptide-1 [GLP-1] receptor agonists], sodium-glucose cotransporter 2 [SGLT-2] inhibitors, peptidyl peptidase-4 inhibitors).